Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 01, 2015 6:30 PM ET

Biotechnology

Company Overview of Visterra, Inc.

Company Overview

Visterra, Inc., a biotechnology company, develops antibodies for infectious diseases. It focuses on developing therapeutics for infectious diseases, such as influenza; viral diseases, such as HIV; and dengue virus. The company uses its Atomic Interaction Network analysis to identify disease targets and design effective therapeutics; and Hierotope Platform, which identifies an area or epitope on the target protein, glycoprotein, or glycan that is fundamental to its structure and function. Its product pipeline comprises VIS410 for Influenza that exhibits direct anti-viral activity through inhibition of hemagglutinin-mediated cell membrane fusion; dengue antibody programs; and collaborative pro...

One Kendall Square

Suite B3301

Cambridge, MA 02139

United States

Founded in 2007

Phone:

617-498-1070

Fax:

617-498-1073

Key Executives for Visterra, Inc.

Chief Executive Officer, President and Director
Age: 56
Founder and Chairman of the Board
Age: 52
Founder and Director
Age: 50
Chief Financial Officer and Chief Operating Officer
Age: 54
Chief Medical Officer
Compensation as of Fiscal Year 2015.

Visterra, Inc. Key Developments

Visterra Partners with Agency for Science, Technology and Research to Develop VIS513

Visterra, Inc. and the Drug Discovery & Development (D3) unit under the Agency for Science, Technology and Research, Singapore announced a collaboration to further the development of VIS513, Visterra's broadly neutralizing antibody for the treatment of dengue fever. VIS513, which was engineered using Visterra's innovative and proprietary technology, is a humanized monoclonal antibody that is designed to bind and potently neutralize all four serotypes of dengue virus. The company's preclinical studies of VIS513 in animal models have demonstrated a rapid reduction in viral titers after a single systemic administration, which supports its potential use as a single administration treatment for dengue virus infection. The collaboration combines Visterra's expertise in therapeutic antibodies for challenging infectious diseases with D3's proficiency in bringing early stage discoveries into clinical development. D3 and Visterra will also work together with infectious disease experts at Duke-National University of Singapore (Duke-NUS) to generate additional data necessary to initiate clinical trials of VIS513. Upon completion of these activities, D3 and Visterra will advance VIS513 through proof-of-concept clinical trials in humans, which will be conducted in Singapore. Under the terms of the collaboration agreement Visterra retains all rights to develop and commercialize VIS513 globally.

Visterra Announces Additions to its Management Team and Board of Directors

Visterra, Inc. announced two key additions to the company's executive management team and board of directors. José M. Trevejo, MD, PhD, has been appointed Vice President of Development and Akshay Vaishnaw, MD, PhD, of Alnylam Pharmaceuticals, Inc. has been elected to the company's board of directors. In his role as Vice President of Development, Dr. Trevejo will oversee all preclinical and clinical development, as well as regulatory affairs for the company. This includes advancing clinical programs for product candidates from Visterra's pipeline of novel monoclonal antibodies that target infectious diseases, including advancing VIS410 for seasonal and pandemic influenza into phase 2 clinical studies and progressing VIS513 for dengue fever into the clinic. Prior to joining Visterra, Dr. Trevejo served as Medical Director at Genentech, Inc. Dr. Vaishnaw is currently Executive Vice President and Chief Medical Officer of Alnylam Pharmaceuticals, Inc., which he joined in 2006.

Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM

Visterra, Inc. Presents at The JPMorgan 32nd Annual Healthcare Conference, Jan-16-2014 10:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Brian J. G. Pereira, Chief Executive Officer, President and Director.

Similar Private Companies By Industry

Company Name Region
Avelis, LLC United States
Follica, Inc. United States
Cognate TiGenix United States
Sentient Bioscience, Inc. United States
ICOS Corporation United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
October 2, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Visterra, Inc., please visit www.visterrainc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.